GURUFOCUS.COM » STOCK LIST » Basic Materials » Agriculture » Tianjin TEDA Biomedical Engineering Co Ltd (HKSE:08189) » Definitions » ROC %

Tianjin TEDA Biomedical Engineering Co (HKSE:08189) ROC % : 0.00% (As of Jun. 2024)


View and export this data going back to 2002. Start your Free Trial

What is Tianjin TEDA Biomedical Engineering Co ROC %?

ROC % measures how well a company generates cash flow relative to the capital it has invested in its business. It is also called ROIC %. Tianjin TEDA Biomedical Engineering Co's annualized return on capital (ROC %) for the quarter that ended in Jun. 2024 was 0.00%.

As of today (2025-03-26), Tianjin TEDA Biomedical Engineering Co's WACC % is 5.04%. Tianjin TEDA Biomedical Engineering Co's ROC % is -3.13% (calculated using TTM income statement data). Tianjin TEDA Biomedical Engineering Co earns returns that do not match up to its cost of capital. It will destroy value as it grows.


Tianjin TEDA Biomedical Engineering Co ROC % Historical Data

The historical data trend for Tianjin TEDA Biomedical Engineering Co's ROC % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Tianjin TEDA Biomedical Engineering Co ROC % Chart

Tianjin TEDA Biomedical Engineering Co Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
ROC %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -6.61 -1.88 -2.33 -6.36 -3.02

Tianjin TEDA Biomedical Engineering Co Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Jun24
ROC % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -9.33 -7.10 -6.27 11.17 -

Tianjin TEDA Biomedical Engineering Co ROC % Calculation

Tianjin TEDA Biomedical Engineering Co's annualized Return on Capital (ROC %) for the fiscal year that ended in Dec. 2023 is calculated as:

ROC % (A: Dec. 2023 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (A: Dec. 2022 ) + Invested Capital (A: Dec. 2023 ))/ count )
=-10.757 * ( 1 - 8.69% )/( (334.292 + 315.719)/ 2 )
=-9.8222167/325.0055
=-3.02 %

where

Tianjin TEDA Biomedical Engineering Co's annualized Return on Capital (ROC %) for the quarter that ended in Jun. 2024 is calculated as:

ROC % (Q: Jun. 2024 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Dec. 2023 ) + Invested Capital (Q: Jun. 2024 ))/ count )
=0 * ( 1 - 0% )/( (315.719 + 318.264)/ 2 )
=0/316.9915
=0.00 %

where

Note: The Operating Income data used here is four times the quarterly (Jun. 2024) data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Tianjin TEDA Biomedical Engineering Co  (HKSE:08189) ROC % Explanation

ROC % measures how well a company generates cash flow relative to the capital it has invested in its business. It is also called ROIC %. The reason book values of debt and equity are used is because the book values are the capital the company received when issuing the debt or receiving the equity investments.

There are four key components to this definition. The first is the use of operating income or EBIT rather than net income in the numerator. The second is the tax adjustment to this operating income or EBIT, computed as a hypothetical tax based on an effective or marginal tax rate. The third is the use of book values for invested capital, rather than market values. The final is the timing difference; the capital invested is from the end of the prior year whereas the operating income or EBIT is the current year's number.

Why is ROC % important?

Because it costs money to raise capital. A firm that generates higher returns on investment than it costs the company to raise the capital needed for that investment is earning excess returns. A firm that expects to continue generating positive excess returns on new investments in the future will see its value increase as growth increases, whereas a firm that earns returns that do not match up to its cost of capital will destroy value as it grows.

As of today, Tianjin TEDA Biomedical Engineering Co's WACC % is 5.04%. Tianjin TEDA Biomedical Engineering Co's ROC % is -3.13% (calculated using TTM income statement data). Tianjin TEDA Biomedical Engineering Co earns returns that do not match up to its cost of capital. It will destroy value as it grows.


Be Aware

Like ROE % and ROA %, ROC % is calculated with only 12 months of data. Fluctuations in the company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.


Tianjin TEDA Biomedical Engineering Co ROC % Related Terms

Thank you for viewing the detailed overview of Tianjin TEDA Biomedical Engineering Co's ROC % provided by GuruFocus.com. Please click on the following links to see related term pages.


Tianjin TEDA Biomedical Engineering Co Business Description

Traded in Other Exchanges
N/A
Address
No. 80, The 4th Avenue, 9th Floor, Block A2, Tianda Hi-Tech Park, TEDA Tianjin, Tianjin, CHN
Tianjin TEDA Biomedical Engineering Co Ltd is engaged in the research, development, and commercialization of biological compound fertilizers, providing elderly and health care services. It operates in two segments namely; biological compound fertilizers products, and elderly care and health care services. The company generates a majority of its revenue from the Fertilisers products segment which is engaged in manufacturing and selling biological compound fertiliser products, including active fertiliser, mixture with nitrogen, phosphorus, and potassium with various formulas, providing warehousing services, and processing and licensing of the fertiliser products. The People's Republic of China is the primary geographical market for the company.
Executives
Long Ortiz 2101 Beneficial owner

Tianjin TEDA Biomedical Engineering Co Headlines

No Headlines